Skip to search boxSkip to navigationSkip to main content

A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission

  • Y. Boumber(corresponding author)
    ,
  • H. Kantarjian
    ,
  • J. Jorgensen
    ,
  • S. Wen
    ,
  • S. FaDerl
    ,
  • R. Castoro
*Corresponding author for this work
  • University of Texas MD Anderson Cancer Center
Scholary Output:
Contribution to journal
Letter
Research
Peer-review

Open access

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Publication Information

Output type

Scholary Output:
Contribution to journal
Letter
Research
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 2428-2431 (4 pages)

Journal (Volume, Issue Number)

Leukemia (Volume 26, Issue 11)

Publication milestones

  • Published - 11/2012

Publication status

Published - 11/2012

ISSN

0887-6924

Publication IDs

  • Scopus: 84869095050
  • PubMed: 22665218
  • ORCID: /0000-0002-8636-1071/work/68811024

Publication metrics

Metrics

SciVal
citations
40
SciVal
FWCI
4.57
SciVal
Author count
14
SciVal
Paper percentile
90
SciVal
Top percentile
10
Fractional count
1
Fractional count
0.07
Fractional count
13
Fractional count
0.93
Fractional count
1
Fractional count
1
Scopus
citations

PlumX, opens in new tab

Citation count
60
Captures
33

Funding Details

This work was supported in part by the Leukemia SPORE, CA100632 and by a grant from Eisai Pharmaceuticals. We would like to thank Angelo Willems and Carine Seynaeve for their expert technical assistance. The work was financially supported by the International Myeloma Foundation, Fonds voor Wetenschappelijk Onderzoek Vlaanderen (FWO-Vl), Stichting tegen Kanker, King Baudouin Foundation, Multiple Myeloma Research Foundation, the European Stem cell network (EUFP6 MSCNET) and the Onderzoeks-raad Vrije Universiteit Brussel (GOA48, OZR-VUB). E Van Valckenborgh, E Menu and E De Bruyne are postdoctoral fellows, and E Schouppe and K Movahedi are predoctoral fellows of FWO-Vl. JA Van Ginderachter is supported by Stichting tegen Kanker. OT-1 mice were a kind gift of Dr Muriel Moser (ULB, Brussels, Belgium). Non-labeled anti-CCR2 (MC-21) was a gift of Dr Matthias Mack (University of Regensburg, Germany).
FundersFunding numbers
Eisai Pharmaceuticals
-
European Stem cell network
-
Fonds voor Wetenschappelijk Onderzoek Vlaanderen
-
Onderzoeks-raad Vrije Universiteit Brussel
GOA48
NCI
P30CA016672
MMRF
-
IMF
-
Stichting Tegen Kanker
-
kbs-frb
-